EE425 Impact of Inclusion of Finerenone in the Burden of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) in Colombia
Value in Health(2023)
摘要
To estimate the economic burden of CKD-T2D from a social perspective[1] in two scenarios: the standard of care (SoC) used in Colombia and the standard of care plus Finerenone, a nonsteroidal, selective antagonist of the mineralocorticoid receptor studied for the management of adults with CKD (eGFR ≥ 25mL/min with albuminuria) and T2D.
更多查看译文
关键词
finerenone,chronic kidney disease,diabetes
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要